An FDA decision is looming for Alkermes’ ALKS 3831, a treatment for schizophrenia and bipolar I disorder that adds an opioid antagonist to a well-known antipsychotic to negate the weight gain and ...
The FDA approved the antipsychotic combination of olanzapine plus samidorphan (Lybalvi) for adults with schizophrenia or bipolar I disorder, drugmaker Alkermes announced on Tuesday. In schizophrenia, ...
DUBLIN, April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback